Expression and clinical significance of EZH2 and α-SMA in myocardium of patients with rheumatic heart disease with atrial fibrillation

doi:10.12092/j.issn.1009-2501.2019.12.009

Abstract

Abstract:

AIM: To investigate the expression correlation between histone-lysine N-methyltransferase EZH2 and α-SMA in the patients with rheumatic heart disease and atrial fibrillation (AF). METHODS: Tissues of auricula dextra were removed from 20 patients with rheumatic heart disease undergoing cardiac surgery for correction to valvular defect. According to the definition of AF, 20 patients were divided into group of AF group and of sinus rhythm (SR) group (n=10). The collagen deposition in myocardial tissue was detected by Masson's trichrome stain. The expression of EZH2 and α-SMA were detected by immunohistochemistry, qRT-PCR and Western blot. RESULTS:Masson staining results revealed that the collagen deposition and the comparisons of CVF were significantly increased in the AF heart tissue compared with the SR control(P<0.05). Immunohistochemistry indicated that comparing with the SR group; the expressions of EZH2 and α-SMA protein were significantly increased in AF group (P<0.05). Western blot indicated that compared with the SR group, the expressions of EZH2 and α-SMA protein were significantly increased in AF group(P<0.05). Moreover, qRT-PCR found that compared with the SR group, the expressions of EZH2 and α-SMA mRNA were significantly increased in AF group(P<0.05). CONCLUSION: High expressions of EZH2 and α-SMA indicate EZH2 and α-SMA can regulate the development of AF.

Key words: rheumatic heart disease, atrial fibrillation, histone-lysine-N-methyltransferase EZH2, &alpha, smooth muscle actin

CLC Number:

R541.3

XU Shengsong, TAO Hui, SHI Kaihu, DING Jifei. Expression and clinical significance of EZH2 and α-SMA in myocardium of patients with rheumatic heart disease with atrial fibrillation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1371-1375.

References

［1］Giannopoulos G, Vrachatis D, Kossyvakis C, et al. Effect of postablation statin treatment on arrhythmia recurrence in patients with paroxysmal atrial fibrillation［J］. J Cardiovasc Pharmacol, 2018, 72(6):285-290.
［2］Mei B, Liu H, Yang S, et al. Long non-coding RNA expression profile in permanent atrial fibrillation patients with rheumatic heart disease［J］. Eur Rev Med Pharmacol Sci, 2018,22(20):6940-6947.
［3］Tao H, Shi KH, Yang JJ, et al. Epigenetic mechanisms in atrial fibrillation: New insights and future directions［J］. Trends Cardiovasc Med, 2016, 26(4):306-318.
［4］Zhao K, He J, Wang YF, et al. EZH2-mediated epigenetic suppression of EphB3 inhibits gastric cancer proliferation and metastasis by affecting E-cadherin and vimentin expression［J］. Gene, 2018 , 686:118-124.
［5］Wetterslev M,Haase N,Hassager C, et al. New-onset atrial fibrillation in adult critically ill patients: a scoping review［J］ .Intensive Care Med, 2019, undefined: undefined.
［6］Gullón A, Sánchez Fuentes D, López-de-Sá E, et al. Use of oral anticoagulants in complex clinical situations with atrial fibrillation［J］. Med Clin (Barc), 2018,150 Suppl 1:8-24.
［7］Zhang X, Li H, Kou W, et al. Increased plasma microfibrillar-associated protein 4 is associated with atrial fibrillation and more advanced left atrial remodelling［J］ .Arch Med Sci, 2019, 15(3): 632-640.
［8］Nortamo S, Ukkola O, Kiviniemi A, et al. Impaired cardiac autonomic regulation and long-term risk of atrial fibrillation in patients with coronary artery disease［J］. Heart Rhythm, 2018,15(3):334-340.
［9］Zhang D, Hu X, Henning RH, et al. Keeping up the balance: role of HDACs in cardiac proteostasis and therapeutic implications for atrial fibrillation［J］. Cardiovasc Res, 2016, 109(4):519-526.
［10］Zhou Y, Lv X, Qu H, et al. Differential expression of circular RNAs in hepatic tissue in a model of liver fibrosis and functional analysis of their target genes［J］.Hepatol Res, 2019, 49(3): 324-334.
［11］Jalan-Sakrikar N, De Assuncao TM, Shi G, et al. Proteasomal degradation of enhancer of zeste homologue 2 in cholangiocytes promotes biliary fibrosis［J］. Hepatology, 2019.
［12］Tsou PS, Campbell P, Amin MA, et al. Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma［J］. Proc Natl Acad Sci U S A, 2019, 116(9): 3695-3702.
［13］Grindheim JM, Nicetto D, Donahue G, et al. Polycomb repressive complex 2 proteins EZH1 and EZH2 regulate timing of postnatal hepatocyte maturation and fibrosis by repressing genes with euchromatic promoters in mice［J］ .Gastroenterology, 2019, 156(6): 1834-1848.
［14］Zhou X, Xiong C, Tolbert E, et al. Targeting histone methyltransferase enhancer of zeste homolog-2 inhibits renal epithelial-mesenchymal transition and attenuates renal fibrosis［J］. FASEB J, 2018, fj201800237R.
［15］Holm Nielsen S,Willumsen N, Leeming DJ, et al. Serological assessment of activated fibroblasts by alpha-smooth muscle actin (α-SMA): A noninvasive biomarker of activated fibroblasts in lung disorders［J］.Transl Oncol, 2019, 12(2): 368-374.
［16］Yang Y,Chen XX,Li WX, et al. EZH2-mediated repression of Dkk1 promotes hepatic stellate cell activation and hepatic fibrosis［J］.J Cell Mol Med, 2017, 21(10): 2317-2328.

[1]	LIU Huanmiao, CHEN Zhuohui, WU Di, HUANG Xueting, WAN Qiquan. Insulin attenuates the inhibition effect of lipopolysaccharide on Na+-K+-ATPase α1 via PI3K/AKT and PI3K/ERK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 896-902.
[2]	YANG Shucai，ZHANG Li，LIU Liping，DENG Weijie，ZHOU Jie，LIU Hui，ZHANG Baohu，JIN Tao. Effect of hypoxia-inducible factor 2α on chemoresistance of hepatocellular carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 630-636.
[3]	HAN Chenyang, ZHANG Xiaoling, YANG Yi, GUO Li, GUAN Qiaobing. α-synuclein activates NLRP3 inflammatory bodies to mediated nerve cell pyroptosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 637-643.
[4]	ZHENG Qiongna, WU Qiaoqiao, MA Zhele, ZHANG Xianfei, GAN Fangmin, KONG Qingming. Interventional effect of low molecular weight heparin on mice with experimental hepatic fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 511-516.
[5]	YANG Leixi, FENG Kai, FAN Xueting, WEI Yanchun, LIU Tingting, TANG Yiqun. Novel compound HYY-002 inhibits paroxysmal atrial fibrillation in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1347-1352.
[6]	ZHAO Jiangtao, LIANG Yange. Experimental study on the effect of total flavonoids of Pueraria lobata on inflammatory cytokines in rats with inner ear injury induced by isoproterenol [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1003-1007.
[7]	YE Rongfang, LIU Mingyi, XU Yu, ZHANG Yanli, ZHU Dandan, DING Wei, XIONG Yuqing. Effects of miR-1-3p/206/613 on the expression of LXRα and OATP1B1 proteins and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 846-854.
[8]	MAO Qingdong. Efficacy and safety of recombinant human interferon alfa2b oxygen inbreathe for bronchiolitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 927-931.
[9]	ZHOU Hongping, YANG Xingxin, ZHUANG Rangxiao, SHAO Yidan, XI Jianjun, LIAO Li, REN Bailu, WANG Pingping, YU Shuying, SHI Tingting. Effects of activated carbon N-acetylcysteine sustained-release microcapsule on miRNA of non-alcoholic fatty liver disease in young rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 263-270.
[10]	LIU Yue, LIU Yuanyuan, ZHANG Ni, CAO Shilu, ZHANG Xiaojing, LAI Lina. Change and significance of Ero1α expression on endoplasmic reticulum stress induced by hypoxia/reoxygenation in rat cardiomycytes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 972-977.
[11]	XIE Zhen, KANG Hua, HE Licheng, KUANG Rong. Effects and mechanism of deep-sea fish oil on blood lipid in hyperlipidemia rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 870-874.
[12]	LI Xujiong, LIU An, CHEN Yunxia, LI Shufen. Curcumin alleviate intrapulmonary inflammation in rat experimental hepatopulmonary syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 738-742.
[13]	HAN Chao, YANG Liu, ZHANG Qiuling, PAN Jinqiang, XU Jun. Effect of baicalin on airway remodeling of bronchial asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 749-754.
[14]	LIU Yu, ZHANG Ying, WANG Ancai. Effect of rhBNP on chronic systolic heart failure combined with diuretic resistance and concentration of TNF-α and NPY [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 814-820.
[15]	CHEN Yanbin, DENG Shanshan. Effect of Xingnaojing injection on the expression of hypoxia-inducible factor-1α in patients with acute cerebral infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 821-824.